Biopharma Quarter: Key Trends and Events of the Third Quarter of 2009Decision ResourcesDecember 11, 2009 37 Pages - SKU: DECR2523973 |
|
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a
|
more...
|
$3,995.00
|
|
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
5/15/2012 | published by: GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
Summary
GBI Research, the leading
|
more...
|
$3,500.00
|
|
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
4/30/2012 | published by: GBI Research
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules Summary GBI Research, the leading business intelligence provider, has released its latest research
|
more...
|
$3,500.00
|
|
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
4/30/2012 | published by: GBI Research
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation Summary GBI Research, the leading business intelligence provider, has released its latest research “Orphan Disease
|
more...
|
$3,500.00
|
|
Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
4/30/2012 | published by: GBI Research
Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion Summary GBI Research, the leading business intelligence provider, has released its latest research, “Cytotoxic Therapies Market
|
more...
|
$3,500.00
|
|
Research Report on Chinese Bio-pharmaceutical Industry, 2012
3/21/2012 | published by: China Research and Intelligence Co., Ltd.
In China, biological products consist of vaccines, blood products, cytokine, diagnostic reagents and other active agents (including toxins, antigens, allergen, and recombinant DNA products, etc.). In China, animal vaccine belongs to veterinary medicine rather than
|
more...
|
$3,000.00
|
|
Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation
2/29/2012 | published by: GlobalData
Approval of Kalydeco Brings New Hope for CF Patients with G551D Mutation Summary The report is an essential source of information and analysis on the KALYDECO (ivacaftor, VX-770) for the treatment of Cystic Fibrosis (CF) patients with
|
more...
|
$500.00
|
|
Top 194 Generic Pharmaceuticals (Global)
4/1/2012 | published by: Plimsoll Publishing Ltd.
This report is an in-depth financial evaluation of the GlobalGeneric Pharmaceuticals. Using the unique Plimsoll method of analysis, each of the top 194 companies included is individually assessed and ranked against each other and compared
|
more...
|
$1,500.00
|
|
Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates
2/29/2012 | published by: GBI Research
Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates Summary GBI Research’s new report, “Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates”
|
more...
|
$3,500.00
|
|
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
4/2/2012 | published by: GBI Research
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program Summary GBI Research, the leading business intelligence provider, has released its latest research “Pricing and Reimbursement
|
more...
|
$3,500.00
|
Related Markets
Biopharmaceuticals Reports
- Research Report on Chinese Bio-pharmaceutical Industry, 2012
- Regulatory Intelligence on Biologics Recalls – Immunoglobulins and Vaccines are Involved in More Recalls than Other Drug Classes
- Biologics Market in Brazil
- Global Biosimilars Market Forecast to 2015
- Biosimilars: Current Situation & Future Prospects, Worldwide
